(PharmaNewsWire.Com, August 02, 2019 ) Growth in this market is driven by the increasing number of surgical procedures, growing number of regulatory approvals, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries.
The Hemostats market is expected to reach USD 3.03 billion by 2023 from USD 2.14 billion in 2017 at a CAGR of 6.0%.
+ Market Dynamics
+ Drivers
+ Increasing Number of Surgical Procedures
+ Growing Number of Regulatory Approvals
+ Increasing Incidence of Sports-Related Injuries and Spinal Ailments
+ Rising Focus on Effective Blood Loss Management in Patients During Surgeries
The hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. Of all these product segments, the thrombin-based hemostats segment is expected to account for the largest share of the global hemostats market in 2018.
The hemostats market is segmented neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries. The orthopedic surgery segment is expected to account for the largest share of the hemostats market in 2018. The growing geriatric population, increasing incidence of sports injuries, and the growing prevalence of lifestyle disorders (such as arthritis, osteoporosis, and obesity) are some of the major factors responsible for the growth in the number of orthopedic surgeries performed globally.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: